Clinical trial · Interventional
Identification of a New Blood Biomarker for the Diagnosis and Prognosis of Liposarcomas
NCT04224064CI-TRIAL-00085888ESPACErecruitingN/AClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
The main objective of this project is to identify a new non-invasive biological test for the diagnosis of LPS by measuring circulating serine levels. The current gold standard is the detection of Mdm2 amplification by the FISH.
Conditions
Conditions (2)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Atypical Lipomatous Tumor | Atypical Lipomatous Tumor | ONTOLOGY_EXACT | 0.90 |
| Liposarcoma | Liposarcoma | ONTOLOGY_EXACT | 0.90 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Blood sampling | Diagnostic Test | — | UNRESOLVED |
Design
Arms and outcomes
Arms (2)
- type
- EXPERIMENTAL
- label
- Healthy subjects cohort
- description
- A single blood sample will be made in healthy subjects.
- interventionNames
- Diagnostic Test: Blood sampling
- type
- EXPERIMENTAL
- label
- Liposarcoma patients cohort
- description
- Blood samples will be collected at different times: one before induction before surgery and then the second 4 weeks after surgery (+/- 1 week), then every 3 months for 18 months.
- interventionNames
- Diagnostic Test: Blood sampling
Primary outcomes (1)
- measure
- Sensibility and specificity of circulating serine level for LPS diagnosis
- timeFrame
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria for LPS patients cohort: Men/women older than 18 years old, Surgery for : * Localized WD-LPS and DD-LPS, and/or * WD-LPS or DD-LPS local relapse, and/or * WD-LPS or DD-LPS distant relapse and/or * Deep adipocytic tumor greater than 5 cms, suggestive of atypical lipomatous tumor Patient accepting blood sample, Patient who signed informed consent Inclusion Criteria for healthy subjects cohort: Men/women older than 18 years old, Accepting blood sample, Who signed informed consent Matching on sex and age on LPS patient cohort Exclusion Criteria: Presence of NeoAdjuvant Treatment for the present cancer, Unaffiliated patient to French Social Protection System, Patient whose follow up is impossible for psychologic, social, geographic, familial reasons Psychiatric illness that would prevent the patient from giving informed consent or being compliant with the study procedures Patient who have another cancer within the 5 years of the inclusion except in situ breast carcinoma, in situ, basocellular carcinoma. Pregnancy and/or feeding
References
Publications (3)
- BACKGROUNDBurningham Z, Hashibe M, Spector L, Schiffman JD. The epidemiology of sarcoma. Clin Sarcoma Res. 2012 Oct 4;2(1):14. doi: 10.1186/2045-3329-2-14. PMID 23036164
- BACKGROUNDSmolle MA, Tunn PU, Goldenitsch E, Posch F, Szkandera J, Bergovec M, Liegl-Atzwanger B, Leithner A. The Prognostic Impact of Unplanned Excisions in a Cohort of 728 Soft Tissue Sarcoma Patients: A Multicentre Study. Ann Surg Oncol. 2017 Jun;24(6):1596-1605. doi: 10.1245/s10434-017-5776-8. Epub 2017 Jan 20. PMID 28108827
- BACKGROUNDChandrasekar CR, Wafa H, Grimer RJ, Carter SR, Tillman RM, Abudu A. The effect of an unplanned excision of a soft-tissue sarcoma on prognosis. J Bone Joint Surg Br. 2008 Feb;90(2):203-8. doi: 10.1302/0301-620X.90B2.19760. PMID 18256089